BRCA1 and ovarian carcinoma: Plasma sequencing using next-generation sequencing is an emerging companion diagnostic technology for various indications such as BRCA1/2 testing in ovarian cancer, ALK rearrangements in lung cancer and PIK3CA gene mutations in breast cancer patients eligible for treatment with alpelisib [27].